Literature DB >> 11729366

Protein and angiogenic dose-response expression of phVEGF-A(165) gene in rat myocardium.

C Sylvén1, N Sarkar, E Wärdell, A Jämsä, V Drvota, P Blomberg, K Bin Islam.   

Abstract

Therapeutic myocardial angiogenesis by means of transient overexpression of angiogenic growth factors is a potential treatment modality for severe ischemic heart disease. This study was undertaken in the rat to examine effects of phVEGF-A(165) myocardial transfection in terms of dose-response as regards the number of hVEGF-A expressing cells on one hand and on the other angiogenesis. Non-surgical echocardiography-guided intramyocardial injection of phVEGF-A(165) was done into normoxic or hypoxic (10% O(2)) rats. Cardiomyocytes expressing VEGF-A protein, capillary morphology and density were determined after 5 days. VEGF protein expression was seen in rat cardiomyocytes located around the tip of the injection scar and increased dose-dependently (p<0.05). Microvessel density also increased dose-dependently with phVEGF(165) (p<0.05) and with hypoxia (p<0.05). No vascular tumours were observed. In conclusion, direct intramyocardial injection of phVEGF-A(165) in the rat results in a dose-dependent increase both in transfected hVEGF-A protein producing cells and in angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11729366     DOI: 10.1023/a:1012971421128

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  20 in total

Review 1.  Clinical applications of angiogenic growth factors and their inhibitors.

Authors:  N Ferrara; K Alitalo
Journal:  Nat Med       Date:  1999-12       Impact factor: 53.440

2.  Myocardial Doppler tissue velocity improves following myocardial gene therapy with VEGF-A165 plasmid in patients with inoperable angina pectoris.

Authors:  C Sylvén; N Sarkar; A Rück; V Drvota; S Y Hassan; B Lind; A Nygren; Q Källner; P Blomberg; J van der Linden; D Lindblom; L A Brodin; K B Islam
Journal:  Coron Artery Dis       Date:  2001-05       Impact factor: 1.439

Review 3.  Mechanisms of angiogenesis.

Authors:  W Risau
Journal:  Nature       Date:  1997-04-17       Impact factor: 49.962

4.  Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease.

Authors:  J F Symes; D W Losordo; P R Vale; K G Lathi; D D Esakof; M Mayskiy; J M Isner
Journal:  Ann Thorac Surg       Date:  1999-09       Impact factor: 4.330

5.  Direct myocardial transfection in two animal models. Evaluation of parameters affecting gene expression and percutaneous gene delivery.

Authors:  D Gal; L Weir; G Leclerc; J G Pickering; J Hogan; J M Isner
Journal:  Lab Invest       Date:  1993-01       Impact factor: 5.662

6.  Catheter-based myocardial gene transfer utilizing nonfluoroscopic electromechanical left ventricular mapping.

Authors:  P R Vale; D W Losordo; T Tkebuchava; D Chen; C E Milliken; J M Isner
Journal:  J Am Coll Cardiol       Date:  1999-07       Impact factor: 24.094

7.  Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF.

Authors:  A Rivard; M Silver; D Chen; M Kearney; M Magner; B Annex; K Peters; J M Isner
Journal:  Am J Pathol       Date:  1999-02       Impact factor: 4.307

8.  Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization.

Authors:  T Takahashi; C Kalka; H Masuda; D Chen; M Silver; M Kearney; M Magner; J M Isner; T Asahara
Journal:  Nat Med       Date:  1999-04       Impact factor: 53.440

9.  Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization.

Authors:  C Kalka; H Masuda; T Takahashi; W M Kalka-Moll; M Silver; M Kearney; T Li; J M Isner; T Asahara
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

10.  Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart.

Authors:  C A Mack; S R Patel; E A Schwarz; P Zanzonico; R T Hahn; A Ilercil; R B Devereux; S J Goldsmith; T F Christian; T A Sanborn; I Kovesdi; N Hackett; O W Isom; R G Crystal; T K Rosengart
Journal:  J Thorac Cardiovasc Surg       Date:  1998-01       Impact factor: 6.439

View more
  1 in total

1.  Cardiac overexpression of human VEGF(165) by recombinant Semliki Forest virus leads to adverse effects in pressure-induced heart failure.

Authors:  A E Loot; A J M Roks; D Westermann; H-D Orzechowski; C Tschöpe; J C Wilschut; R A Tio; W H van Gilst; R H Henning
Journal:  Neth Heart J       Date:  2007       Impact factor: 2.380

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.